Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma

Cancer Investigation

Volumn 25, Issue 3, 2007, Pages 140-147

  Chiou, Tzeon Jye ^a   Wang, Teng Hsu ^b   Chao, Tsu Yi ^c   Lin, Sheng Fung ^d   Tang, Jih Luh ^e   Chen, Tsai Yun ^f   Chang, Ming Chih ^g   Hsueh, Erh Jung ^h   Chen, Po Min ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g MACKAY MEMORIAL HOSPITAL   (Taiwan)

^h PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Adverse effect; Interferon alpha; Paraprotein response; Refractory multiple myeloma; Thalidomide

Indexed keywords

ALPHA2B INTERFERON; PARAPROTEIN; THADO; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLURRED VISION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LOG RANK TEST; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OPTIMAL DRUG DOSE; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; WEAKNESS; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; SUBCUTANEOUS DRUG ADMINISTRATION; TAIWAN; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PARAPROTEINS; TAIWAN; THALIDOMIDE; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 34347266571     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208808     Document Type: Article

References (0)